|
A-3 . hydrochloride |
|
|
ALX-270-039-M010 |
|
10 mg |
65.00 USD |
|
 |
|
ALX-270-039-M050 |
|
50 mg |
260.00 USD |
|
|
|
|
Ac-RCGVPD-NH2 |
|
|
ALX-260-165-M001 |
|
1 mg |
45.00 USD |
|
|
|
ALX-260-165-M005 |
|
5 mg |
180.00 USD |
|
|
|
|
H-Ala-Pro-Arg-Thr-Pro-Gly-Gly-Arg-Arg-OH |
|
|
ALX-151-024-M001 |
|
1 mg |
95.00 USD |
|
|
|
ALX-151-024-M005 |
|
5 mg |
380.00 USD |
|
|
|
|
Altenusin |
|
|
ALX-350-325-M001 |
|
1 mg |
110.00 USD |
|
|
|
ALX-350-325-M005 |
|
5 mg |
380.00 USD |
|
|
|
|
(-)-Arctigenin |
|
|
ALX-350-312-M025 |
|
25 mg |
70.00 USD |
|
|
|
|
(-)-Arctiin |
|
|
ALX-350-318-M025 |
|
25 mg |
60.00 USD |
|
|
|
|
Ascochlorin |
|
|
ALX-350-334-MC05 |
|
0.5 mg |
320.00 USD |
|
|
|
|
Aspirin |
|
|
ALX-430-115-G005 |
|
5 g |
10.00 USD |
|
|
|
|
Azaspiracid-1 |
|
|
ALX-350-366-C001 |
|
1 µg |
180.00 USD |
|
|
|
|
Azelaoyl-PAF |
|
|
ALX-301-013-M001 |
|
1 mg |
58.00 USD |
|
|
|
ALX-301-013-M005 |
|
5 mg |
261.00 USD |
|
|
|
|
Baccatin III, 10-Deacetyl- |
|
|
ALX-351-006-M005 |
|
5 mg |
190.00 USD |
|
|
|
ALX-351-006-M025 |
|
25 mg |
590.00 USD |
|
|
|
|
Bistheonellide A |
|
|
ALX-350-287-C100 |
|
100 µg |
470.00 USD |
|
|
|
|
(+)-Brefeldin A |
|
|
ALX-350-019-M005 |
|
5 mg |
80.00 USD |
|
|
|
ALX-350-019-M010 |
|
10 mg |
130.00 USD |
|
|
|
ALX-350-019-M025 |
|
25 mg |
270.00 USD |
|
|
|
ALX-350-019-M050 |
|
50 mg |
420.00 USD |
|
|
|
|
VE-cadherin, Soluble ELISA Kit |
|
|
ALX-850-059-KI01 |
|
1 Kit |
619.00 USD |
|
|
|
|
Caffeic acid methyl ester |
|
|
ALX-350-226-M050 |
|
50 mg |
60.00 USD |
|
|
|
|
Calphostin C |
|
|
ALX-350-027-M001 |
|
1 mg |
595.00 USD |
|
|
|
ALX-350-027-C100 |
|
100 µg |
85.00 USD |
|
|
|
|
Catharanthine . tartrate |
|
|
ALX-350-101-G001 |
|
1 g |
430.00 USD |
|
|
|
ALX-350-101-M100 |
|
100 mg |
160.00 USD |
|
|
|
|
sCD44std, Soluble (human) ELISA Kit |
|
|
ALX-850-053-KI01 |
|
1 Kit |
619.00 USD |
|
|
|
|
sCD44var(v5), Soluble (human) ELISA Kit |
|
|
ALX-850-054-KI01 |
|
1 Kit |
619.00 USD |
|
|
|
|
sCD44var(v6), Soluble (human) ELISA Kit |
|
|
ALX-850-055-KI01 |
|
1 Kit |
619.00 USD |
|
|
|
